Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Calithera Biosciences, Inc. Rose as Much as 25.2% Today

By Maxx Chatsko - Feb 16, 2018 at 1:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The tiny pharma stock received an upgrade from a prominent analyst.

What happened

Shares of Calithera Biosciences (CALA -0.35%) soared more than 25% after receiving an upgrade from analysts at Citigroup. The stock is now rated as a "buy," instead of "neutral." While that may seem insignificant, it could signal a bottom for shares, which have been steadily falling since November 2017.

To be fair, longtime Calithera Biosciences shareholders have little to complain about after the stock's epic rise in 2017 from just over $4 per share to $20 per share. The rise was well-deserved thanks to partnerships and expanded collaborations with Incyte and Bristol-Myers Squibb. As of 12:05 p.m. EST, the stock had settled to a 23.7% gain.

A person sitting on the ground using their laptop with cash money falling around him.

Image source: Getty Images.

So what

Calithera Biosciences has a promising oncology pipeline comprised of two named compounds and at least two other drug candidates in earlier stage trials. Its lead drug candidate is a glutaminase inhibitor called CB-839, which is being evaluated in four different phase 2 studies. It's also the drug in the partnership with Bristol-Myers Squibb. Incyte is helping to develop an arginase inhibitor called INCB001158, although it's in phase 1 trials.

While the pipeline will be expensive to develop, Wall Street has been cheering the fact that two deep-pocketed partners are on board. That should definitely help, as should the company's $166 million cash hoard calculated at the end of September.

Now what

Friday's news is seemingly insignificant, and may prove to be meaningless in the long run, but it could also remind investors that Wall Street isn't giving up on Calithera Biosciences despite its recent slide. There's still a long way to go for the tiny pharma, but it holds an intriguing amount of potential for a $300 million company.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Calithera Biosciences, Inc. Stock Quote
Calithera Biosciences, Inc.
$2.86 (-0.35%) $0.01
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$78.70 (-1.60%) $-1.28
Incyte Corporation Stock Quote
Incyte Corporation
$75.63 (-2.24%) $-1.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.